Virtu Financial LLC bought a new stake in Kenvue Inc. (NYSE:KVUE - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 59,457 shares of the company's stock, valued at approximately $1,269,000.
Several other institutional investors also recently modified their holdings of KVUE. Millstone Evans Group LLC bought a new position in Kenvue in the fourth quarter valued at approximately $565,000. TD Private Client Wealth LLC boosted its position in shares of Kenvue by 116.6% in the 4th quarter. TD Private Client Wealth LLC now owns 279,728 shares of the company's stock worth $5,972,000 after purchasing an additional 150,601 shares during the last quarter. Berkeley Capital Partners LLC grew its stake in shares of Kenvue by 1.2% during the fourth quarter. Berkeley Capital Partners LLC now owns 69,250 shares of the company's stock worth $1,478,000 after purchasing an additional 816 shares during the period. Teacher Retirement System of Texas grew its stake in shares of Kenvue by 87.2% during the fourth quarter. Teacher Retirement System of Texas now owns 308,467 shares of the company's stock worth $6,586,000 after purchasing an additional 143,648 shares during the period. Finally, Royal London Asset Management Ltd. increased its holdings in Kenvue by 7.4% in the fourth quarter. Royal London Asset Management Ltd. now owns 2,334,433 shares of the company's stock valued at $49,840,000 after purchasing an additional 161,605 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.
Kenvue Stock Up 0.5 %
NYSE KVUE traded up $0.12 during trading on Thursday, hitting $23.52. The stock had a trading volume of 13,790,573 shares, compared to its average volume of 16,136,490. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The company's 50-day moving average price is $22.22 and its two-hundred day moving average price is $22.45. The company has a market capitalization of $44.95 billion, a PE ratio of 44.38, a P/E/G ratio of 2.62 and a beta of 1.25.
Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, sell-side analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.
Kenvue Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were issued a dividend of $0.205 per share. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.49%. Kenvue's payout ratio is presently 154.72%.
Analyst Ratings Changes
Several research firms have recently issued reports on KVUE. Evercore ISI initiated coverage on Kenvue in a research report on Monday. They set an "in-line" rating and a $25.00 target price for the company. Piper Sandler increased their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a report on Monday, February 24th. Canaccord Genuity Group lifted their price target on shares of Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. Citigroup lowered their price objective on shares of Kenvue from $25.00 to $21.00 and set a "neutral" rating for the company in a research report on Wednesday, January 15th. Finally, Royal Bank of Canada reiterated a "sector perform" rating and set a $24.00 target price on shares of Kenvue in a report on Monday, February 3rd. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $24.00.
View Our Latest Stock Report on Kenvue
About Kenvue
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Featured Stories
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
